Nucleic Acid-Based Therapeutics for Glioblastoma

Author(s): Alexei Shir, Alexander Levitzki, Ernst Wagner, Shoshana Klein, Manfred Ogris

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 11 , Issue 8 , 2011

Become EABM
Become Reviewer


Nucleic acid based therapeutics offer the possibility of tailor-made treatment of malignant diseases. For recurrent glioblastoma multiforme (GBM), the most aggressive type of brain tumor, no accepted treatment exists, making therapeutically active nucleic acids a viable option. In this review, current preclinical and clinical studies harnessing the potential of antitumoral nucleic acids for GBM treatment will be considered. These include gene therapy to over-express antitumoral gene products, RNA interference to knock down components that promote tumor progression, and the tumor-targeted delivery of antitumoral double stranded RNA. Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids.

Keywords: Gene therapy, oncolytic virotherapy, poly IC, polyplexes, RNAi, Antisense RNA, RNA Interference, RNA polymerase, helicases, Oncolytic Viruses

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [693 - 699]
Pages: 7
DOI: 10.2174/187152011797378599
Price: $65

Article Metrics

PDF: 9